🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — May 23, 2026

This digest covers $346.2 million in high-value federal obligations from a single day (May 23, 2026), split between one civilian and one defense-related award. The dominant theme is specialized aircraft procurement for the FAA, with Textron Aviation Inc. securing a $208.4 million sole-source delivery order for modified King Air 360ER aircraft—the highest-conviction signal given its firm-fixed-price structure and non-competitive award. The second award, a $137.8 million cost-plus-award-fee IT services contract to Booz Allen Hamilton via GSA FEDSIM, is neutral due to limited margin upside and an anomalous negative outlay. Key risk: Textron’s non-competitive award may face protest or delay, and Booz Allen’s negative outlay requires clarification in upcoming filings.

2 total filings
· daily

General Federal Contracts — May 23, 2026

The two contracts analyzed represent a total obligation of $346.2 million, with a 50/50 split between defense and civilian agencies, though the dominant theme is civilian aviation and IT services. The highest-conviction signal is Textron Inc.'s $208.4 million sole-source FAA award for modified King Air 360ER aircraft, which underscores a durable competitive moat in specialized government aircraft. The neutral Booz Allen Hamilton $137.8 million GSA FEDSIM award (with a $679.9M ceiling) signals stable IT services demand but carries an anomalous negative outlay that warrants scrutiny. Key risk is the non-competitive nature of the Textron award potentially attracting protests, while the Booz Allen contract's cost-plus pricing limits margin upside despite low execution risk.

2 total filings
· daily

Biotech Small-Cap Approvals — May 22, 2026

The May 22, 2026 small-cap biotech approval stream delivered 9 generic (biosimilar) approvals with zero NMEs, zero label expansions, and zero novel therapeutic signals. All approvals are classified as neutral, low-materiality events, reflecting a period of incremental generic competition rather than pipeline-driven value creation. The most notable approval is VENETOCLAX (DR REDDYS), a biosimilar to AbbVie/Roche’s blockbuster oncology drug, which introduces pricing pressure on a ~$2B+ franchise. The period is dominated by legacy generic entrants (LINACLOTIDE, MIRTAZAPINE, TADALAFIL) with no therapeutic area clustering or breakthrough designations. Key risk: the VENETOCLAX biosimilar entry could accelerate IRA-driven price erosion for small-molecule oncology drugs, though commercial impact is deferred given DR REDDYS’s launch timing and interchangeability status.

9 total filings
· daily

NME Blockbuster Approvals — May 22, 2026

The single FDA approval in this period is BAXDROSTAT (BAXFENDY) from AstraZeneca, classified as a 'FALLBACK' type with a bullish signal. This is an NME approval granted Priority Review, indicating the FDA recognized significant unmet need. With no biosimilars or label expansions in the mix, the digest is narrowly focused on this single event. The highest-conviction signal is AstraZeneca's execution in securing an NME approval, which reinforces its pipeline strength, though the absence of commercial details (peak sales, pricing, market position) limits the depth of the investment thesis. The key watch item is the lack of disclosed exclusivity and pricing data, which are critical for assessing revenue potential and IRA exposure risk.

1 total filings
· daily

Big Pharma Approvals — May 22, 2026

During this period, the FDA issued 2 approvals, both classified as 'FALLBACK' type with bullish signals, comprising 1 NME (BAXDROSTAT) and 1 label expansion (VENETOCLAX). The dominant therapeutic area theme is hematology-oncology, with both approvals targeting blood cancers. The highest-conviction signal is AstraZeneca's NME approval of BAXDROSTAT (BAXFENDY) with Priority Review, representing a novel therapy with strong regulatory endorsement and significant commercial potential. A key risk is the lack of disclosed peak sales estimates and exclusivity data, limiting precise valuation, though the bullish signals suggest favorable market reception. No biosimilars or bearish signals were recorded, indicating a clean, catalyst-rich period for the sector.

2 total filings
· daily

Orphan Drug Approvals — May 22, 2026

This digest covers 4 label expansion approvals from May 15-20, 2026, with zero NMEs, biosimilars, or first-cycle new indications. All four approvals are classified as 'FALLBACK' type and carry bullish signals of moderate strength (5/10) and materiality (5/10), but lack disclosed commercial data. The dominant therapeutic area is oncology, with three of four approvals targeting cancer indications. The highest-conviction signal is the dual label expansion for Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki), which received two separate approvals on the same day, signaling aggressive lifecycle management and potential market expansion for this blockbuster ADC. A key watch item is the lack of specificity in approval details—without disclosed peak sales, exclusivity, or pricing data, the investment thesis remains opaque and requires follow-up from sponsor disclosures or clinical trial readouts.

4 total filings
· daily

New Drug Approvals (Original) — May 22, 2026

The May 22, 2026 FDA approval digest is dominated by 10 'Other' approvals, with zero NMEs, zero biosimilars (as formally classified), and zero label expansions. The sole bullish signal is AstraZeneca's NME approval of BAXDROSTAT (BAXFENDY), granted Priority Review, representing the highest-conviction event in an otherwise low-catalyst period. The remaining nine approvals are all generic/biosimilar entries for mature molecules (linaclotide, mirtazapine, venetoclax, tadalafil, etc.) from sponsors including Actavis, Dr. Reddy’s, and Zydus, generating neutral signals due to lack of disclosed commercial data. Key risk: the absence of NMEs or label expansions signals a quiet period for innovative catalysts, though AstraZeneca’s Priority Review NME provides a differentiated pipeline signal.

10 total filings
· daily

DHS Homeland Security Contracts — May 22, 2026

The two DHS contracts awarded on May 19-20, 2026, totaling $267.5 million, are entirely civilian (DHS/CBP) and signal sustained investment in Southwest border security infrastructure and aviation assets. The highest-conviction signal is Davenport Aviation Inc.'s $95.5 million firm-fixed-price award for 10 H125 helicopters, which carries high execution risk due to zero outlayed funds and a compressed 2-year delivery timeline. LMI Consulting's $172 million quality assurance contract for border wall construction provides a steady ~$62.5 million annual revenue stream but is limited by no options beyond the base period. Key risks include firm-fixed-price execution on both contracts and potential budget volatility under a continuing resolution, while opportunities lie in follow-on DHS aviation and border infrastructure spending.

2 total filings
· daily

VA Healthcare & Services Contracts — May 22, 2026

This digest covers a single $153.1M civilian contract from the Department of Veterans Affairs awarded to GOVCIO, LLC, with no defense-related exposure. The contract, a time-and-materials delivery order for portfolio products and sustainment, signals stable but unremarkable revenue for GOVCIO through March 2026, with medium execution risk due to the pricing model. The highest-conviction signal is neutral, reflecting a large, competitive win that lacks a clear competitive moat or set-aside advantage. Key risks include medium pricing risk from the time-and-materials structure and potential revenue concentration for GOVCIO on this single award.

1 total filings
· daily

New Federal Contractors — May 22, 2026

This digest covers $913.4 million in new federal contract obligations awarded across six contracts, all civilian (0/6 defense-related), with an average signal strength of 5.5/10. The dominant theme is civilian agency IT modernization and border security infrastructure, led by the Department of Homeland Security (two contracts totaling $267.5M) and the General Services Administration (one $296.8M award). The highest-conviction signal is a bullish sole-source 8(a) award to Akumen, Inc. ($91.7M) from the State Department, indicating durable non-competitive revenue. A key risk is the unusual negative outlayed amount (-$13,398) on the largest contract (General Dynamics Information Technology, $296.8M), which may signal execution or accounting issues. Overall, the digest points to stable civilian spending but limited defense exposure and mixed execution signals.

6 total filings
· daily

Significant Contract Modifications ($10M+) — May 22, 2026

This digest covers six civilian agency contract actions totaling $913.4 million, with zero defense-related awards, underscoring a pure civilian-sector procurement story. The dominant theme is border security and IT modernization, led by a $296.8M General Dynamics Information Technology engineering services award from GSA and a $172.0M LMI Consulting border wall quality assurance order from DHS/CBP. The highest-conviction signal is a sole-source 8(a) award to Akumen, Inc. for $91.7M from the State Department, indicating durable non-competitive revenue. A key risk is the negative outlayed amount (-$13,398) on the GDIT contract, which raises execution status questions, and the high fixed-price risk on the $95.5M Davenport Aviation helicopter order and the $104.4M Carahsoft Salesforce license deal.

6 total filings
· daily

Contract Deobligations Alert — May 22, 2026

This digest covers $913.4 million in total obligations across 6 contracts, all civilian (0% defense), signaling a notable concentration of federal spending outside the Department of Defense. The dominant theme is border security and IT modernization, with the Department of Homeland Security (DHS) accounting for $267.5 million across two awards to LMI Consulting and Davenport Aviation, both tied to Southwest border infrastructure. The highest-conviction signal is Akumen, Inc.'s $91.7 million sole-source 8(a) award from the State Department, which offers revenue certainty with limited competitive pressure. A key risk is the General Dynamics Information Technology contract's negative outlayed amount (-$13,398), which may indicate execution issues or accounting anomalies that warrant monitoring.

6 total filings
· daily

Federal Professional Services Contracts — May 22, 2026

Over a single-day period, two federal professional services contracts totaling $468.8 million were awarded, both civilian in nature with zero defense exposure. The dominant theme is infrastructure quality assurance and engineering support, with the General Services Administration (GSA) and Department of Homeland Security (DHS) as the key agencies. The highest-conviction signal is General Dynamics Information Technology's $296.8 million GSA engineering services award, though its materiality is tempered by a negative outlayed amount (-$13,398) that raises execution ambiguity. A key risk is the fixed-price structure of LMI Consulting's $172.0 million border wall quality assurance contract, which shifts cost overrun risk to the contractor and lacks options for upside. Overall, the digest reflects stable but non-transformative civilian services spending, with no bullish or bearish signals flagged.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — May 22, 2026

This digest covers $349.2 million in federal IT and cybersecurity contracts awarded entirely by civilian agencies (0% defense), signaling sustained non-defense digital modernization spending. The Department of Veterans Affairs ($153.1M to GOVCIO), USDA ($104.4M to Carahsoft), and Department of State ($91.7M to Akumen) dominate, with a clear theme of enterprise SaaS adoption and IT sustainment. The highest-conviction signal is Akumen's sole-source 8(a) award, which provides durable revenue with no competitive pressure through October 2026. Key risk: Carahsoft's fixed-price Salesforce ELA carries high pricing risk if usage exceeds estimates, and all three contracts face Continuing Resolution vulnerability in FY2027 budget negotiations.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — May 22, 2026

This digest covers $726.2 million in mega-contracts ($100M+) awarded entirely by civilian agencies, with zero defense-related obligations. The dominant theme is civilian IT modernization and infrastructure support, led by General Dynamics Information Technology's $296.8M GSA engineering services award (though parent entity ambiguity and negative outlayed funding raise execution questions) and Carahsoft Technology Corp's $104.4M USDA Salesforce enterprise license agreement signaling sustained SaaS adoption. The highest-conviction signal is Carahsoft's $277M ceiling potential, indicating strong upside if options are exercised. Key risks include the negative outlayed amount on the GDIT contract and the fixed-price structure on both the Carahsoft and LMI Consulting awards, which shift cost risk to contractors. No bullish or bearish signals were identified; all four contracts are rated neutral with an average signal strength of 5.3/10.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 22, 2026

This digest covers $913.4 million in high-value federal grants awarded on a single day, with zero defense-related contracts, underscoring a purely civilian procurement theme. The dominant agency is the Department of Homeland Security (two awards totaling $267.5 million), followed by GSA ($296.8 million), VA ($153.1 million), USDA ($104.4 million), and State ($91.7 million). The highest-conviction signal is Akumen, Inc.'s $91.7 million sole-source 8(a) award from State, offering revenue certainty with limited competitive pressure. A key risk is the General Dynamics Information Technology contract, where a negative outlayed amount (-$13,398) on a $296.8 million obligation raises questions about execution status or accounting adjustments.

6 total filings
· daily

General Federal Contracts — May 22, 2026

This digest covers six civilian-agency contracts totaling $913.4 million, with zero defense-related awards, underscoring a non-DoD procurement focus. The dominant theme is IT modernization and border security infrastructure, led by General Dynamics Information Technology ($296.8M), LMI Consulting ($172M), and GOVCIO ($153.1M). The highest-conviction signal is Akumen, Inc.'s $91.7M sole-source 8(a) award from the State Department, which offers revenue certainty via non-competitive advantage. Key risks include execution pressure on Davenport Aviation's $95.5M firm-fixed-price helicopter contract and the negative outlayed amount on the General Dynamics award, which may indicate funding or performance issues. Investors should watch for option exercises on Carahsoft's $277M USDA Salesforce deal and the June 2024 end date of the General Dynamics contract for recompete signals.

6 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 22, 2026

The May 22, 2026, S&P 500 Technology filings present a mixed picture dominated by annual meeting results and capital events, with limited operational data but several critical strategic signals. Zoom Communications stands out as the sole filing with meaningful period-over-period financial data, reporting a robust 67% YoY net income surge to $426M driven by improving operating leverage and investment gains, though its cash position declined sharply by 30% due to aggressive buybacks. The SPAC filing from Snow Rothschild Acquisition Corp. seeks $200M with significant dilution risks for public investors, while United Community Banks' acquisition of Peach State Bancshares at a $789M asset base signals consolidation in regional banking. Insider activity is absent from these filings, but director election results reveal notable shareholder dissent at SBA Communications (Laurie Bowen with 11.3% against), ServiceNow (Eric Yuan with 22.7% against), and Community Bancorp (17% broker non-votes), suggesting governance concerns. Capital allocation trends show a mix of modest dividend increases (Richmond Mutual at $0.15/share) and aggressive buybacks (Zoom reducing shares 1.9% sequentially). The overall portfolio theme is one of corporate governance alignment through annual meetings, with Zoom's operational strength providing the most actionable financial insight.

6 high priority 5 medium 11 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 22, 2026

This batch of 17 NASDAQ-100 filings reveals a diverging landscape: while stalwarts like Amazon and PepsiCo show procedural strength and solid credit access, emerging and transitioning companies (Welsbach/Evolution Metals, Faraday Future, Zoom) are reporting dramatic financial swings, high cash burn, or strategic inflection points. A clear period-over-period theme is the widening loss profiles at newer public entities—Welsbach/Evolution Metals swung from an $18M loss to a $440M GAAP loss—driven by non-cash fair value charges tied to complex post-business-combination accounting, obscuring underlying operational progress. Conversely, Zoom delivered a standout 67% YoY net income surge on improved margins and cost discipline, signaling maturation from growth to profitability mode. Insider activity is minimal across the filings, but shareholder voting dissent (e.g., 10.7M shares against one director at SBA, 7% negative say-on-pay at CCC) and high broker non-votes (17% at Community Bancorp/VT) suggest pockets of governance friction. Capital allocation patterns show a mix: dividend declarations (Richmond Mutual, Community Financial), share buyback continuation (Zoom), and merger expansion (United Community Banks acquiring Peach State). Forward-looking catalysts include Faraday Future's raised shipment target (1,500 units, +50%) and a $100M convertible note facility for Evolution Metals, alongside a shelf registration from Critical Metals Corp., signaling future capital raises. The most actionable insights cluster around three high-materiality narratives: Zoom’s profitability pivot, Faraday Future's listing survival gambit, and Evolution Metals' capacity ramp.

5 high priority 12 medium 17 total filings